23:51 , Oct 19, 2017 |  BC Innovations  |  Finance

Broad umbrella

In its $50 million tie-up with the Broad Institute of MIT and Harvard, Deerfield Management is looking to forge a new mold of partnership with an academic organization that allows it to efficiently survey early...
07:00 , Aug 18, 2016 |  BC Innovations  |  Emerging Company Profile

Negative thinking for brain cancer

Sapience Therapeutics Inc. is developing a dominant-negative form of the transcription factor ATF5 to target refractory glioblastoma without touching the surrounding tissue, taking advantage of the fact the brain stops expressing the protein in early...
00:47 , Jul 13, 2016 |  BC Extra  |  Financial News

Cancer newco Sapience raises $22.5M

Sapience Therapeutics Inc. (Scarsdale, N.Y.) raised $22.5 million in an untranched series A round led by Eshelman Ventures. Celgene Corp. (NASDAQ:CELG), TaiAn Technologies and Healthlink Capital also participated. Sapience's lead program, ST-36, is a preclinical...
07:00 , Jun 3, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Cancer Brain cancer Activating transcription factor 5 (ATF5); cAMP responsive element binding protein 3-like 2 (CREB3L2) Studies in vitro and in mice suggest that inhibiting CREB3L2 could help treat glioblastoma. CREB3L2 is...